A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Altimmune, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 88,400 shares of ALT stock, worth $678,028. This represents 0.0% of its overall portfolio holdings.

Number of Shares
88,400
Previous 69,400 27.38%
Holding current value
$678,028
Previous $461,000 17.57%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.5 - $8.1 $104,500 - $153,900
19,000 Added 27.38%
88,400 $542,000
Q2 2024

Aug 14, 2024

BUY
$5.91 - $10.23 $410,154 - $709,962
69,400 New
69,400 $461,000
Q3 2023

Nov 14, 2023

SELL
$2.4 - $3.45 $49,920 - $71,760
-20,800 Reduced 2.17%
937,000 $2.44 Million
Q2 2023

Aug 14, 2023

BUY
$3.45 - $5.97 $22,425 - $38,805
6,500 Added 0.68%
957,800 $3.38 Million
Q1 2023

May 15, 2023

BUY
$4.19 - $16.83 $108,940 - $437,579
26,000 Added 2.81%
951,300 $4.01 Million
Q4 2022

Feb 14, 2023

BUY
$8.74 - $16.45 $493,810 - $929,425
56,500 Added 6.5%
925,300 $15.2 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $1.09 Million - $2.29 Million
102,200 Added 13.33%
868,800 $11.1 Million
Q2 2022

Aug 15, 2022

BUY
$3.94 - $11.77 $298,652 - $892,166
75,800 Added 10.97%
766,600 $8.97 Million
Q1 2022

May 16, 2022

BUY
$5.9 - $9.45 $788,240 - $1.26 Million
133,600 Added 23.98%
690,800 $4.21 Million
Q4 2021

Feb 14, 2022

BUY
$8.69 - $12.48 $4.84 Million - $6.95 Million
557,200 New
557,200 $5.1 Million
Q2 2021

Aug 16, 2021

SELL
$9.85 - $16.46 $2.33 Million - $3.89 Million
-236,200 Closed
0 $0
Q1 2021

May 17, 2021

SELL
$12.71 - $24.31 $1.38 Million - $2.64 Million
-108,400 Reduced 31.46%
236,200 $3.34 Million
Q4 2020

Feb 16, 2021

SELL
$7.84 - $14.22 $1.15 Million - $2.09 Million
-147,300 Reduced 29.95%
344,600 $3.89 Million
Q3 2020

Nov 16, 2020

BUY
$9.93 - $33.26 $4.88 Million - $16.4 Million
491,900 New
491,900 $6.49 Million

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $376M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track David A. Siegel's Portfolio

Track David A. Siegel Portfolio

Follow David A. Siegel (Two Sigma Advisers, LP) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Advisers, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Advisers, LP and David A. Siegel with notifications on news.